| Name | Title | Contact Details |
|---|
Founded in 1988 in Queensbury, N.Y., U.S., AngioDynamics is today a NASDAQ-listed public company. We are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. Our diverse product line includes market-leading radiofrequency ablation and NanoKnife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. AngioDynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. AngioDynamics believes it is well poised to continue that trend. Looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patient care by providing the highest-quality, best-performing products.
Chase Ergonomics Inc. is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Baxa sub Baxter International is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Laclede Inc is a Compton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SteadyMed Therapeutics, Inc. is a Specialty Pharmaceutical Company. SteadyMed leverages its PatchPump platform to develop its own therapeutic portfolio and partners to optimize the delivery of high volume (greater than two mL), high value, small molecule or biologic drugs. Our family of PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner. SteadyMed aspires to redefine the parenteral therapeutics experience for patients dependent upon large doses of intravenous and subcutaneous medications: Extending the limits of parenteral therapeutics to restore freedom, joy and dignity to patients’ lives.